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Abstract
Background: Williams syndrome (WS) and autism spectrum disorder (ASD) are neurodevelopmental disorders that
demonstrate overlapping genetic associations, dichotomous sociobehavioral phenotypes, and dichotomous
pathological differences in neuronal distribution in key social brain areas, including the prefrontal cortex and the
amygdala. The serotonergic system is critical to many processes underlying neurodevelopment and is additionally
an important neuromodulator associated with behavioral variation. The amygdala is heavily innervated by
serotonergic projections, suggesting that the serotonergic system is a significant mediator of neuronal activity.
Disruptions to the serotonergic system, and atypical structure and function of the amygdala, are implicated in both
WS and ASD.
Methods: We quantified the serotonergic axon density in the four major subdivisions of the amygdala in the
postmortem brains of individuals diagnosed with ASD and WS and neurotypical (NT) brains.
Results: We found opposing directions of change in serotonergic innervation in the two disorders, with ASD
displaying an increase in serotonergic axons compared to NT and WS displaying a decrease. Significant differences
(p < 0.05) were observed between WS and ASD data sets across multiple amygdala nuclei.
Limitations: This study is limited by the availability of human postmortem tissue. Small sample size is an
unavoidable limitation of most postmortem human brain research and particularly postmortem research in rare
disorders.
Conclusions: Differential alterations to serotonergic innervation of the amygdala may contribute to differences in
sociobehavioral phenotype in WS and ASD. These findings will inform future work identifying targets for future
therapeutics in these and other disorders characterized by atypical social behavior.
Background
Williams syndrome (WS) is a rare neurodevelopmental
disorder (~ 1/10,000 [1]) caused by a hemizygous deletion
on chromosome band 7q11.23 and associated with a distinct
socioaffective phenotype which includes an atypically strong
drive for social engagement, an uninhibited propensity to
approach and socially engage with strangers, decreased
social anxiety, and increased attention to faces [2, 3]. In
contrast, autism spectrum disorder (ASD) is a common
neurodevelopmental disorder (1/59 in the USA [4]) with a
highly complex and heterogeneous genetic etiology and a
behavioral phenotype characterized in part by reduced drive
for social engagement and decreased attention/atypical pro-
cessing of the eyes of others, an important social stimulus in
humans [5, 6]. Our previous studies in the postmortem
brains of individuals with ASD [7] and WS [8, 9] have
demonstrated opposing patterns of difference compared to
healthy controls in the number of neurons in the same key
social brain areas, paralleling differences in social behavior.
Together, these findings suggest that a direct comparison of
these two disorders may offer a unique human model in
which to examine changes in the brain that may contribute
to the biological underpinnings of social behavior and,
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furthermore, may help elucidate critical neural targets for
potential therapeutics in disorders accompanied by sociobe-
havioral difficulties.
The amygdala, a limbic structure located in the medial
temporal lobe, is critically implicated in social behavior
and emotion. Neuroimaging studies have demonstrated
structural and functional abnormalities of the amygdala
in many neurological disorders that are accompanied by
atypical social behavior, including in the WS and ASD
amygdala [10–13]. However, the relationship between
structure and function of the amygdala and behavior
remains elusive. The amygdala is composed of several
nuclei that can be distinguished from each other based
on histological criteria [14], and tracer and lesion studies
in animal models suggest that the structural heterogen-
eity of these nuclei correspond to functional differences.
Four nuclei in particular, the lateral, basal, accessory
basal, and central nuclei, are significantly implicated in
two distinct but overlapping processing loops. The lateral,
basal, and accessory basal nuclei are thought be involved in
cognitive processing given the significant bidirectional con-
nectivity to association areas in the frontal and temporal
lobes [15–17]. In contrast, the central nucleus is critical to
the autonomic loop of processing in the amygdala, as it
lacks connectivity to association cortex, but receives heavy
intra-amygdala projections, and serves as the major output
nucleus of the amygdala to brain stem and hypothalamic
regulatory centers [15–17]. In our postmortem studies of
the amygdala in WS [9] and ASD [7, 18], we found that
the lateral nucleus was selectively vulnerable in both disor-
ders, such that compared to NT, there was a significant
increase in neuron number in the lateral nucleus in WS
and a significant decrease in neuron number in the lateral
nucleus in ASD. The lateral nucleus is the primary site of
cortical input into the amygdala and an important region
for cognitive processing of external stimuli, so these
targeted alterations, in opposing directions of change, may
contribute to differential atypical processing of social stim-
uli in WS and ASD.
While differences in neuron number likely contribute to
differences in amygdala function, neuronal activity is fre-
quently modulated by neurotransmitter systems. Serotonin
is a monoamine that has been implicated in a diverse array
of functions in the brain. As a neurotransmitter, serotonin
plays a role in several processes of neural development and
neural plasticity, including neurogenesis, neural differenti-
ation, axon myelination, and synapse formation and re-
modeling [19, 20]. Serotonin is also a key neuromodulator
in several processes of emotion and cognition, including
anxiety and social behavior [21]. WS and ASD diagnoses
share a high comorbidity with anxiety disorders, and the
effective use of selective serotonin uptake inhibitors (SSRIs)
in mitigating symptoms of severe anxiety in patients with
WS and ASD implicates involvement of the serotonergic
system in both disorders [22, 23]. Furthermore, studies
in animal models have found evidence of altered sero-
tonergic metabolism and synthesis in WS and ASD that
are associated with characteristic behavioral and neuro-
anatomical phenotypes [24–26]. Neuronal activity in
the amygdala is heavily modulated by serotonergic
axons, and disruptions to amygdala serotonergic che-
moarchitecture may contribute to neuropathologies
underlying atypical social behavior, such as the dichotom-
ous behavioral phenotypes of WS and ASD.
A key component of the serotonergic function within
the brain is serotonin transporter (SERT), which is
involved in serotonin reuptake back into the presynaptic
terminal. Maternal SERT function has been demon-
strated to have a profound effect on neural development
in offspring in animal models [27]. Animal studies have
additionally found significant associations between SERT
expression and behavior [28, 29]. In humans, histological
methods that label SERT expression in preserved brain
tissue can give insight into the chemoarchitecture and
anatomy of the serotonin system. Atypical SERT axon
density in postmortem brains has been observed in the
cortex in other neurological disorders with affective
behavioral phenotypes, including schizophrenia [30] and
victims of suicide [31, 32]. However, no study to date
has quantified SERT axon density across the major
subdivisions of the postmortem human amygdala in any
disorder or disease, including ASD and WS. Here, we
utilized immunohistochemical methods to determine the
density of SERT immunoreactive (SERT-ir) axons in the
lateral, basal, accessory basal, and central nuclei of the
amygdala in WS and ASD, and we compared these
results with our data on SERT-ir axon density in neuro-
typical (NT) postmortem brains, as previously reported
in Lew et al. [33], in order to test the hypothesis that
serotonergic chemoarchitecture of targeted amygdaloid
nuclei are disrupted in ASD and WS. Specifically, given
previous qualitative observations of global increases in
SERT axon density in ASD [34, 35] and a pattern of
opposing directions of change in WS and ASD cyto-
architecture [7, 8, 18], we predicted SERT axon density
of the amygdala would be increased in ASD and decreased
in WS compared to NT and that the basolateral nuclei
would demonstrate the greatest differences between the
two disorders.
Methods
The data sets included in this study were obtained from
the postmortem amygdala of a total of 20 subjects, com-
posed of six age-matched adult sets (NT, ASD, WS) and
one age-, sex-, and hemisphere-matched WS-NT infant
pair (see Table 1 for subject background). A correspond-
ing ASD infant could not be included in this study, as
ASD is not formally diagnosed until around 2.5 years of
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age at the earliest [36]. The data set obtained from the
six adult NT subjects was previously reported by us in
an earlier publication [33]. The adult WS and ASD tis-
sue and the WS-NT infant pair was processed and data
was collected following identical methods. Only subjects
free of seizures or other neurological disorders were
used. Amygdala tissue from individuals diagnosed with
ASD prior to death was obtained from the laboratory of
Cynthia Schumann (MIND Institute, UC Davis School
of Medicine). Amygdala tissue from individuals diag-
nosed with WS derived from the Ursula Bellugi Williams
Syndrome Brain Collection, an ongoing donation-based
program run by the Laboratory for Human Comparative
Neuroanatomy at UC San Diego (Semendeferi, PI), in
collaboration with the NIH NeuroBioBank at the Uni-
versity of Maryland. Fluorescence in situ hybridization
(FISH) probes for elastin, a gene consistently deleted in
the WS hemideletion, were used to determine genetic
diagnosis in the WS cases, and all WS subjects used in
this study demonstrated the typical WS genetic deletion.
Mutations and deletions of the elastin gene are associ-
ated with supravalvular aortic stenosis, a heart defect
that is prevalent in WS, and notably, cardiac complica-
tions was the cause of death in five of the seven WS sub-
jects included in this study. Diagnosis for ASD subjects
was assessed based on results of the Autism Diagnostic
Interview-Revised and other medical records [7]. Mean
age and age range for adult subjects were similar across all
three groups included in the analysis (age mean, age range
in years: NT = 45, 19–69; ASD = 41, 20–64; WS = 41, 17–
69). One hemisphere (right or left, based on availability)
was analyzed per subject. A lack of hemispheric asym-
metry has been observed in the human amygdala in both
histological and neuroimaging studies [37, 38] suggesting
a single hemisphere is sufficient for analysis. Diagnostic
groups were not matched for sex or hemisphere due to
the limited availability of postmortem human brain tissue,
and particularly brain tissue from individuals with neuro-
developmental disorders, which is exceptionally rare.
Tissue processing
One brain hemisphere from each subject was immersed in
10% buffered formalin after autopsy (see Table 1 for post-
mortem interval) and remained in formalin until section-
ing. Tissue blocks containing the entire rostrocaudal extent
of the amygdala were extracted from the whole hemisphere
of the brain. Extracted blocks were saturated in a cryopro-
tectant solution of sucrose and 0.1M phosphate buffer,
frozen with dry ice, and cut along the coronal plane using
a Leica SM sliding microtome. Tissue was cut in either
alternating 80 μm and 40 μm sections (WS tissue and NT
tissue from NIH NeuroBioBank) or alternating 100 μm and
Table 1 Subject background
Subject ID Age at death Diagnosis Sex Hemisphere Cause of death Postmortem
interval (hours)
5183 107 days Neurotypical Male Right Sudden infant death syndrome 13
WS 7 114 days Williams syndrome Male Right Multiple organ failure 30
WS 10 17 years Williams syndrome Male Right Cardiac complications 24
4916 19 years Neurotypical Male Right Drowning 5
H-10-01 20 years Autism spectrum disorder Male Right Motor vehicle accident 24
WS 15 25 years Williams syndrome Female Right Cardiac complications 30
H-11-02 27 years Neurotypical Male Left Cardiovascular disease 16
H-6-04 28 years Autism spectrum disorder Male Left Monoxide poisoning 18
WS 14 42 years Williams syndrome Female Right Cardiac complications 18
H-7-02 42 years Autism spectrum disorder Male Right Cardiac arrest 24
WS 9 43 years Williams syndrome Female Right Cardiac complications 12
5758 43 years Neurotypical Female Right Sepsis 22
H-6-00 44 years Autism spectrum disorder Male Left Cardiovascular disease 31
H-19-01 44 years Neurotypical Male Left Unknown 26
H-1-01 44 years Autism spectrum disorder Male Left Pulmonary Embolism 20
WS 8 48 years Williams syndrome Male Left Respiratory illness 30
H-4-02 64 years Autism spectrum disorder Male Right Sepsis 18.5
H-11-98 67 years Neurotypical Male Left Unknown ?
WS 13 69 years Williams syndrome Male Right Cardiac complications 8
5943 69 years Neurotypical Male Right Acute coronary artery thrombosis 23
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50 μm sections (ASD tissue and NT tissue from the
Schumann collection). A 1-in-10 series of either 80 μm or
100 μm sections per individual was mounted and stained
for Nissl substance, and a 1-in-20 series of either 40 μm or
50 μm sections per individual was stained with mouse
monoclonal antibody against SERT (MAB5618, EMD
Millipore, Billerica, MA) using the heat-based antigen
retrieval and immunohistochemical staining protocol de-
scribed in our previous publication [33].
Data collection
Adult data was collected by CL and infant data was collected
by KG, after establishing inter-rater reliability with > 95%
concordance. Data was collected using the Stereoinvestiga-
tor software suite (MBF BioScience, Williston, VT) on a Dell
workstation with a 30.48 centimeter (cm) by 53.34 cm moni-
tor, receiving live video feed from a Lumenera color video
camera (Ottawa, Ontario) attached to an Eclipse 80i micro-
scope equipped with a Ludl MAC5000 stage (Hawthorn,
NY) and a Heiden z-axis encoder (Plymouth, MN). For each
section examined, boundaries of the amygdaloid nuclei were
first traced in Stereoinvestigator at × 1 magnification, utiliz-
ing an adjacent section from the Nissl-stained series as a
visual aid during tracing to ensure precision of boundaries
(described in detail in [9, 14]). After boundaries on the
SERT-ir stained sections were identified (Fig. 1), the Stereo-
investigator Spaceballs probe, which utilizes systematic
random sampling for accurate stereologic quantification,
was employed to estimate SERT-ir axon length at × 100
magnification (1.4 numerical aperture, oil lens), using the
parameters described in our previous publication [33]. Total
axon length density was calculated by dividing the total axon
length by the planimetric reference volume [39, 40].
Analyses of data
All data analyses were performed using Prism statistical
software (v.8, GraphPad Software, La Jolla, CA). Spearman
rank-order correlation tests were used to identify any age,
sex, or post-mortem interval (PMI) effects on SERT-ir
axon density, and data for all subjects was run through a
Grubbs’ test (P < 0.05) to detect possible outliers. Given
the small sample size of the data sets, non-parametric stat-
istical methods were used. The Kruskal-Wallis test with
Dunn’s test for multiple comparisons was employed to
examine differences in SERT-ir axon density in the lateral,
basal, accessory basal, and central nuclei between each
group. While the infant pair was included in the analyses
of NT-WS comparisons, only adult subjects were included
in NT-ASD and ASD-WS comparisons due to the un-
availability of an ASD age-matched infant. The difference
between mean density of SERT-ir axons in ASD and WS
was calculated as the percentage of mean density in NT
subjects (only adult NT subjects included for comparison
Fig. 1 Micrograph showing the four regions of interest in the amygdala in each diagnostic group. The first photo of each row shows the whole
amygdala with boundaries of the lateral, basal, accessory basal, and central nuclei (scale bar = 5 mm). The remaining photos in each row show
SERT-ir stained fibers in each nucleus examined at × 60 magnification (scale bar = 50 μm)
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with ASD; all NT subjects included for comparison with
WS).
Results
Stereological results of mean SERT-ir axon density and
standard deviation in each nucleus in NT, ASD, and WS
are reported in Table 2. One subject in the WS data set,
WS 14, was found to be an outlier by the Grubbs outlier
test and so was excluded from the WS mean values and
all statistical analyses, although individual values of this
subject are included in Fig. 2. No correlations were
found between age, sex, or postmortem interval and
SERT-ir axon density. As observed in our previous ana-
lyses of the postmortem amygdala in WS and ASD [7, 8],
no significant differences in planimetric volume of any
nucleus examined were found between the three groups.
SERT-ir axon densities in the WS and NT infant subjects,
although lower than the adult means, were within the
standard deviation of the adults in their diagnostic group
(Tables 2 and 3; Figs. 2 and 3).
Mean SERT-ir axon density in ASD was greater than
WS in all nuclei examined (Table 2; Fig. 3). The differ-
ence between ASD and WS reached significance in the
lateral, basal, and accessory basal nuclei (p = 0.0425, p =
0.0466, p = 0.0365, respectively; Table 3). No significant
differences were found between NT and ASD or NT and
WS in any nucleus of the amygdala examined. In ASD,
mean SERT-ir axon density was slightly increased in the
lateral and basal nuclei, similar in the accessory basal
nucleus, and slightly decreased in the central nucleus
compared to NT (Fig. 3; Tables 2 and 4). Mean SERT-ir
axon density was decreased in WS compared to NT in
all four nuclei, and the difference between the two
groups was largest and approaching statistical signifi-
cance in the basal (p = 0.0513) and accessory basal nuclei
(p = 0.0513; Tables 2, 3, and 4).
Discussion
This is the first quantitative stereological study to examine
serotonergic innervation of the major amygdala subdivi-
sions in two neurodevelopmental disorders characterized
by dichotomous socio-affective behavioral phenotypes. We
found significant differences in serotonergic innervation of
the amygdala between WS and ASD. Furthermore, WS and
ASD displayed quantitative changes in opposing directions
compared to neurotypical controls. These findings contrib-
ute to a growing body of literature [7–9, 18] in WS and
ASD which demonstrate that both disorders display select-
ive vulnerability of similar targets in the social brain, but in
quantitatively opposing directions of change compared to
healthy controls. This pattern parallels the dichotomous
sociobehavioral phenotypes of the two disorders, suggesting
that the microanatomical changes in neural structure of
these regions may contribute to behavioral differences.
Specifically, in the present study, we found trends of a
slight increase in mean SERT-ir axon density in ASD com-
pared to NT and a decrease in mean SERT-ir axon density
in WS compared to NT (Tables 2, 3, and 4; Fig. 3). Differ-
ences between WS and NT are greater than differences
between ASD and NT in most nuclei, and the decrease in
mean SERT-ir axon density in WS compared to NT
approaches statistical significance in the basal and accessory
basal nuclei (p = 0.0513 for both nuclei). Differences
between ASD and WS are more robust: mean SERT-ir
axon density in ASD is greater than WS in all nuclei exam-
ined, and as we predicted, these differences are significant
in the basolateral nuclei, which demonstrate significant
connectivity to association cortex, including the prefrontal
cortex, another region preferentially targeted in both disor-
ders [8, 41]. Additionally, the present dichotomous findings
in the basolateral nuclei of the amygdala in WS and ASD
parallel the dichotomy of change in neuron number in the
same regions of interest in the two disorders: neuron num-
ber in the basolateral nuclei is decreased in ASD compared
to NT [7, 18] and increased in WS compared to NT [9].
Given the role of serotonin in the regulation of several
neurodevelopmental processes, including neurogenesis,
neuronal differentiation, neuropil formation, axon myelin-
ation, and synaptogenesis [19, 42–45], perhaps the dichot-
omous amygdala pathologies observed in WS and ASD in
these two domains, neuron number and SERT axon dens-
ity, could be related to the effect of different manifestations
of serotonergic disruption to amygdala cellular develop-
ment and seemingly opposing behavioral phenotypes [46].
Table 2 Mean SERT-ir axon density and standard deviation in micrometers (μm/μm3) in each nucleus of the amygdala in
neurotypical, autism spectrum disorder, and Williams syndrome brains
Diagnosis Mean SERT-ir axon density and standard deviation (μm/μm3)
Lateral Basal Accessory basal Central
Neurotypical (adults only) 0.00368 ± 0.00101 0.00458 ± 0.00182 0.00572 ± 0.00270 0.00656 ± 0.00309
Neurotypical (all subjects) 0.00347 ± 0.0011 0.00437 ± 0.00175 0.00532 ± 0.00268 0.00615 ± 0.00302
Autism spectrum disorder 0.00501 ± 0.00174 0.00528 ± 0.00154 0.00581 ± 0.00088 0.00563 ± 0.00088
Williams syndrome (adults only) 0.00384 ± 0.00240 0.00432 ± 0.00296 0.00399 ± 0.00223 0.00504 ± 0.00268
Williams syndrome (all subjects) 0.00289 ± 0.00067 0.00314 ± 0.00071 0.00312 ± 0.00075 0.00418 ± 0.00188
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Fig. 2 Stereological estimates of SERT-ir axon density in the lateral, basal, accessory basal, and central nuclei of the amygdala of individual
subjects in each diagnostic group
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While the similar pattern of differences in behavioral
phenotype and SERT-ir axon density in WS and ASD are
intriguing, the relationship between serotonergic innerv-
ation of the amygdala and behavior is unclear. A recent
study found that mice with homozygous and hemizygous
knockouts of the SERT gene have increased anxiety,
enhanced fear acquisition, and disrupted inhibition in the
amygdala [29], indicating that a possible role of SERT in
social behavior may be related to the modulation of reactiv-
ity of the amygdala in response to stimuli with emotional
valence. Typical activation and reactivity of the amygdala in
response to emotional stimuli, such as faces, is crucial to
determining the emotional valence of stimuli for appropri-
ate behavioral response. In humans, activation of the amyg-
dala in response to faces in general, as well as positive
emotion faces (such as “happy”) and negative emotion faces
(such as “angry” or “fearful”), are parts of different emo-
tional valence cascades which contribute to appropriate
sociobehavioral response. Both individuals with ASD and
individuals with WS have demonstrated atypical activation
of the amygdala in response to human faces. Specifically, in-
dividuals with ASD display hyperactivation of the amygdala
in response to human faces and are avoidant of the eye
region, in which much of emotionally relevant social
cues are displayed in humans, suggesting a negatively
valenced overarousal of the amygdala in response to
social stimuli in ASD which may contribute to social
avoidance behaviors [5, 47–49]. Individuals with WS, in
contrast, display hypoactivation of the amygdala in re-
sponse to negative emotion faces and hyperactivation in
response to positive emotion faces, suggesting disrup-
tion of autonomic processing in response to both posi-
tive and negative emotionally valenced stimuli, which
may contribute to the atypically strong prosocial drive
characteristic of the disorder [10, 50, 51].
Comparative studies examining serotonergic innervation
of the amygdala in closely related species may help shed
light on how different patterns of serotonergic innervation
might contribute to socio-affective behavior. Bonobos and
chimpanzees are two closely related apes and are the clos-
est living relatives to humans. Bonobos typically respond
to conflict with prosocial strategies [52, 53], while chim-
panzees more frequently respond to conflict with aggres-
sion [54]. These behavioral differences are thought to be
Table 3 P values of NT compared to ASD, WS, and WS.
Comparisons with ASD includes only the adult subjects in NT
and WS due to lack of an infant age match in the ASD data set
Comparison Lateral Basal Accessory basal Central
NT vs ASD 0.4684 0.8470 > 0.9999 > 0.9999
NT vs WS 0.4200 0.1950 0.0513 0.3460
ASD vs WS 0.0425* 0.0466* 0.0365* 0.4693
* indicicates statistical significance p < 0.05
Fig. 3 Mean SERT-ir axon density in the lateral, basal, accessory basal, and central nuclei of the amygdala in the adult subjects of each diagnostic
group. The WS and NT adult means are overlaid by values of the WS and NT infant subjects (WS 7 and 5183, respectively) denoted by asterisks.
Lines represent standard deviation of the mean. As observed in the figure, while WS and NT infant values are in the lower range of the adult
values, they fall within the standard deviation of the adult mean
Table 4 % difference of mean SERT-ir axon density in ASD and
WS compared to NT in each nucleus of the amygdala
Nucleus ASD (%) WS (%)
Lateral + 36.1 − 21.5
Basal + 15.3 − 31.4
Accessory basal + 1.6 − 45.5
Central − 14.2 − 36.3
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mediated in part by differences in emotional reactivity
between species [55]. SERT axon density in the postmor-
tem amygdala is lower in chimpanzees relative to bonobos
and humans and more similar between bonobos and
humans than between bonobos and chimpanzees [33, 40].
While species-specific differences are not directly compar-
able to differences across human neuropathologies, the
observation that SERT-ir axon density in the amygdala is
more similar in humans and bonobos, two highly pro-
social species, than in phylogenetically close chimpanzees
and bonobos, implicates the role of serotonergic innerv-
ation of the amygdala in social behavior more generally.
While the association between differences in serotonergic
innervation of the amygdala and behavioral phenotype in
WS and ASD are speculative, genetic evidence suggests dis-
ruptions to the serotonergic system are a feature of both
disorders. One possible genetic link to serotonergic disrup-
tion of the amygdala is GTF2IRD1, a general transcription
factor included in the WS deletion that is linked to the
characteristic WS behavioral phenotype [56] and also impli-
cated as a common site of allelic variation in autism [57].
Genetically altered mice with a deletion of GTF2IRD1 dem-
onstrate altered serotonergic metabolism in the amygdala
and frontal cortex, as well as reduced fear and aggression
compared to wild-type mice [24, 26]. Another possible
mechanism could be related to genetic variation of sero-
tonin transporter genes, which have been linked to cogni-
tive and behavioral differences in primates [58]. In addition
to GTF2IRD1, several other genetic polymorphisms linked
to ASD are found in genes involved in serotonin trans-
porter signaling and function [59–62], and high concentra-
tion of serotonin in the blood, called hyperserotonemia,
occurs in about one third of autism cases [63]. Blood levels
of serotonin are normal in most cases of WS [64]; however,
two separate studies have reported on a total of four cases
in which patients with the common WS genetic deletion
display hyperserotonemia, along with social and communi-
cative deficits diagnostic of autism rather than WS [65, 66].
The researchers of the later study [66] also genotyped the
SERT polymorphism (5-HTTLPR) for the two subjects they
examined and found both were homozygous for the short
allele (5-HTTLPR s). Tordjman and colleagues suggest that
that the deviation from typical WS phenotype displayed by
the two subjects in their study could be due to an inter-
action of WS genetic deletion with other genetic factors,
such as the 5-HTTLPR polymorphism. The 5-HTTLPR
polymorphism has been linked to socio-affective behavioral
variation in humans and non-human primates [67, 68], and
the 5-HTTLPR s allele is associated with heightened amyg-
dala reactivity [69, 70] and stronger amygdala-prefrontal
functional connectivity [71] in healthy subjects. Further-
more, the 5-HTTLPR s allele is thought to be a genetic risk
factor for neuropathologies associated with deficits in affect
and social behaviors [58, 72]. This polymorphism may
contribute to the present findings in the WS and ASD
amygdala, as well as the characteristic behavioral pheno-
types. A future project aimed at genotyping the 5-HTTLPR
polymorphism in the subjects of this study would shed light
on the possible effects of this polymorphism to the WS and
ASD phenotypes.
Limitations
The sample size of this study is limited by the availability
of tissue. The available material is further subjected to an
elaborate immunochemical staining that often requires
further exclusion of subjects to ensure that only highest
quality tissue is used for data collection.
Despite this limitation, we found robust differences
between the WS and ASD groups, suggesting differences
between NT and the two disorders could potentially
reach significance with the addition of a few more
subjects.
Conclusions
The present study is the first quantitative stereological
study to examine serotonergic innervation of the major
amygdala nuclei in two closely linked neurodevelopmental
disorders with dichotomous atypical sociobehavioral phe-
notypes. We found that quantitative differences in SERT-ir
axon density in the amygdala in WS and ASD parallel the
opposing differences between the two disorders that we
previously observed in neuronal distribution of the amyg-
dala. Additionally, these dichotomous findings of atypical
microstructure of the amygdala in WS and ASD parallel
the dichotomous sociobehavioral phenotype of these two
disorders. The serotonergic system is crucial to both neur-
onal development and behavioral modulation. The present
findings of opposing disruptions to the serotonergic system
in ASD and WS may contribute to differential atypical
development of the amygdala and subsequent differences
in amygdala reactivity to social stimuli in WS and ASD.
Given the frequent use of SSRIs in patients with WS and
ASD [22, 23], yet the relative lack of knowledge of the
mechanisms involved, more studies that examine the role
of serotonin in the etiology and phenotype of WS and
ASD are needed to inform treatment and identify targets
of future, more effective therapeutics in these disorders.
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